ns 1619 has been researched along with Hypercapnia in 1 studies
NS 1619: structure given in first source
NS 1619 : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which the hydrogens at positions 1 and 5 are replaced are replaced by 2-hydroxy-5-(trifluoromethyl)phenyl and trifluoromethyl groups, respectively. It is an opener/activator of the large-conductance calcium-activated potassium channel (Bkca).
Hypercapnia: A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Bryan, RM | 1 |
| Pelligrino, DA | 1 |
1 other study available for ns 1619 and Hypercapnia
| Article | Year |
|---|---|
Calcium-dependent and ATP-sensitive potassium channels and the 'permissive' function of cyclic GMP in hypercapnia-induced pial arteriolar relaxation.
Topics: Adenosine Triphosphate; Animals; Benzimidazoles; Blood Pressure; Calcium; Carbon Dioxide; Cerebral A | 1998 |